These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 28002883)
21. Type-II NADH Dehydrogenase (NDH-2): a promising therapeutic target for antitubercular and antibacterial drug discovery. Sellamuthu S; Singh M; Kumar A; Singh SK Expert Opin Ther Targets; 2017 Jun; 21(6):559-570. PubMed ID: 28472892 [TBL] [Abstract][Full Text] [Related]
22. Small Molecule Mediated Restoration of Mitochondrial Function Augments Anti-Mycobacterial Activity of Human Macrophages Subjected to Cholesterol Induced Asymptomatic Dyslipidemia. Asalla S; Mohareer K; Banerjee S Front Cell Infect Microbiol; 2017; 7():439. PubMed ID: 29067283 [No Abstract] [Full Text] [Related]
23. [Recent progress in mycobacteriology]. Okada M; Kobayashi K Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602 [TBL] [Abstract][Full Text] [Related]
24. Colworth prize lecture 2016: exploiting new biological targets from a whole-cell phenotypic screening campaign for TB drug discovery. Moynihan PJ; Besra GS Microbiology (Reading); 2017 Oct; 163(10):1385-1388. PubMed ID: 28893361 [TBL] [Abstract][Full Text] [Related]
25. Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme. Mittal P; Sinha R; Kumar A; Singh P; Ngasainao MR; Singh A; Singh IK Curr Top Med Chem; 2020; 20(5):390-408. PubMed ID: 31924156 [TBL] [Abstract][Full Text] [Related]
26. The relevance of persisters in tuberculosis drug discovery. Mandal S; Njikan S; Kumar A; Early JV; Parish T Microbiology (Reading); 2019 May; 165(5):492-499. PubMed ID: 30775961 [TBL] [Abstract][Full Text] [Related]
27. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. Tomioka H Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755 [TBL] [Abstract][Full Text] [Related]
35. Comprehensive Comparative Analysis of Cholesterol Catabolic Genes/Proteins in Mycobacterial Species. van Wyk R; van Wyk M; Mashele SS; Nelson DR; Syed K Int J Mol Sci; 2019 Feb; 20(5):. PubMed ID: 30818787 [TBL] [Abstract][Full Text] [Related]
38. Not to wake a sleeping giant: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection. Lin MY; Ottenhoff TH Biol Chem; 2008 May; 389(5):497-511. PubMed ID: 18953716 [TBL] [Abstract][Full Text] [Related]
39. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis. Jackson M; McNeil MR; Brennan PJ Future Microbiol; 2013 Jul; 8(7):855-75. PubMed ID: 23841633 [TBL] [Abstract][Full Text] [Related]
40. Genes and regulatory networks involved in persistence of Mycobacterium tuberculosis. Wang X; Wang H; Xie J Sci China Life Sci; 2011 Apr; 54(4):300-10. PubMed ID: 21267668 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]